Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PIR +9.8%, SHIP +9.7%, HIMX +5.4%, (reiterates the Q3 guidance and its business outlook for the remainder of 2016)
- ACN +3.3%, PEP +2.7%, SCHN +2.2%, CAG +2.2%
M&A news: AMTD +4.3% (Bloomberg report that the company may be interested in acquiring Scottrade)
Select oil/gas related names showing strength: STO +2.1%, RDS.A +1.6%, TOT +1.3%, BP +0.9%
Other news:
Select oil/gas related names showing strength: STO +2.1%, RDS.A +1.6%, TOT +1.3%, BP +0.9%
Other news:
- AEGR +34.5% (announces Juxtapid capsules approved in Japan for the treatment of homozygous familial hypercholesterolemia)
- CATB +33.9% (Catabasis Pharmaceuticals and Sarepta Therapeutics (SRPT) announce a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy)
- GNCA +19.6% (announces its ongoing Phase 2b trial evaluating a new Phase 3-ready formulation of GEN-003 for the treatment of genital herpes achieved its primary endpoint)
- ARWR +17.5% (Arrowhead & Amgen (AMGN) announce two license and collaboration agreements to develop and commercialize RNA interference therapies)
- GSAT +5.8% (NASA completes test flight using Globalstar and ADS-B Technologies' ALAS Aviation Tracking Solution)
- RGSE +3.1% (continued strength)
- NSU +1.9% (updates on its Timok Project in Serbia)
- SRPT +1.2% (announces first patient dosed in Phase III clinical trial of SRP-4045 and SRP-4053 for the treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 skipping)
Analyst comments:
- ABEO +7.3% (target raised to $14 at Maxim Group )
- BCEI +5.7% (upgraded to Hold at Stifel)
- EBAY +3.6% (upgraded to Buy from Hold at Deutsche Bank)
- NMBL +3.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- INCY +1.9% (upgraded to Outperform from Mkt Perform at Raymond James)